medigraphic.com
ISSN 2007-8013 (Impreso)
Órgano oficial de la Universidad Autónoma de Sinaloa

2022, Número 2

<< Anterior Siguiente >>

Rev Med UAS 2022; 12 (2)


Inestabilidad de Microsatélites como marcador biológico para la administración de Pembrolizumab

Fernández-Galindo MA, Moreno-Ortiz JM, Contreras-Gutiérrez JA, Martínez-Félix JI, Guerrero-Valdez M, Beltrán-Ontiveros SA

Idioma: Español
Referencias bibliográficas: 40
Paginas: 135-142
Archivo PDF: 263.96 Kb.


RESUMEN

Los microsatélites son secuencias cortas de ADN repetidas en tándem, distribuidas dentro del genoma, los cuales son propensos a errores en la replicación. El sistema Mismatch Repair (MMR), se encarga de identificar, señalar y reparar bases mal emparejadas, principalmente en secuencias repetitivas de ADN. La inactivación de cualquiera de los genes que codifican para las proteínas MMR puede provocar cambios en la longitud de los microsatélites causando un fenotipo hipermutable conocido como inestabilidad de microsatélites (MSI), vía de tumorigénesis bien establecida relacionada con la aparición, progresión y pronóstico de diversas neopla-sias malignas. Debido a la gran cantidad de mutaciones somáticas, los tumores MSI tienen mayor sensibilidad a la inmunoterapia. La FDA ha aprobado un anticuerpo monoclonal como tratamiento para pacientes pediátricos y adultos con tumores sólidos MSI, el cual ha demostrado una actividad antitumoral sólida y duradera y un perfil de seguridad manejable contra varias neoplasias malignas avanzadas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Yuza K, Nagahashi M, Watanabe S, Takabe K, Wakai T. Hypermutation and microsate-llite instability in gastrointestinal cancers. Oncotarget. 2017;8(67):112103-112115. Published 2017 Dec 1. doi:10.18632/onco-target.22783

  2. De' Angelis GL, Bottarelli L, Azzoni C, De´Angelis N, Leandro G, Di Mario F, et al. Microsatellite instability in colorectal cancer. Acta Biomed. 2018;89(9-S):97-101. Publis-hed 2018 Dec 17. doi:10.23750/abm.v89i9-S.7960

  3. Kim DG, An JY, Kim H, Shin SJ, Choi S, Seo WJ, et al. Clinical Implications of Microsate-llite Instability in Early Gastric Cancer. J Gas-tric Cancer. 2019;19(4):427-437. doi:10.5230/jgc.2019.19.e38

  4. Jiricny J. Postreplicative mismatch repair. Cold Spring Harb Perspect Biol. 2013;5(4):a012633. Published 2013 Apr 1. doi:10.1101/cshperspect.a012633

  5. Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspecti-ves, and new treatment approaches. Cell Mol Life Sci. 2018;75(22):4151-4162. doi:10.1007/s00018-018-2906-9

  6. Yuza K, Nagahashi M, Watanabe S, Takabe K, Wakai T. Hypermutation and microsate-llite instability in gastrointestinal cancers. Oncotarget. 2017;8(67):112103-112115. Published 2017 Dec 1. doi:10.18632/onco-target.22783

  7. Yang G, Zheng RY, Jin ZS. Correlations bet-ween microsatellite instability and the biolo-gical behaviour of tumours. J Cancer Res Clin Oncol. 2019;145(12):2891-2899. doi:10.1007/s00432-019-03053-4

  8. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite ins-tability detection by next generation sequen-cing. Clin Chem. 2014;60(9):1192-1199. doi:10.1373/clinchem.2014.223677

  9. Yamamoto H, Imai K. Microsatellite instabi-lity: an update. Arch Toxicol. 2015;89(6):899-921. doi:10.1007/s00204-015-1474-0

  10. Choi YY, Bae JM, An JY, Kwong IG, Cho I, Shin HB, et al. Is microsatellite instability a prognostic marker in gastric cancer? A sys-tematic review with meta-analysis. J Surg Oncol. 2014;110(2):129-135. doi:10.1002/jso.23618

  11. Smyth EC, Wotherspoon A, Peckitt C, Gon-zalez D, Hulkki-Wilson S, Eltahir Z, et al. Mis-match Repair Deficiency, Microsatellite Ins-tability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3(9):1197-1203. doi:10.1001/jamaon-col.2016.6762

  12. de la Chapelle A, Hampel H. Clinical rele-vance of microsatellite instability in colorec-tal cancer. J Clin Oncol. 2010;28(20):3380-3387. doi:10.1200/JCO.2009.27.0652

  13. Yan L, Zhang W. Precision medicine beco-mes reality-tumor type-agnostic therapy. Cancer Commun (Lond). 2018;38(1):6. Pu-blished 2018 Mar 31. doi:10.1186/s40880-018-0274-3

  14. Hause RJ, Pritchard CC, Shendure J, Sali-pante SJ. Classification and characterization of microsatellite instability across 18 cancer types [published correction appears in Nat Med. 2017 Oct 6;23 (10 ):1241] [published correction appears in Nat Med. 2018 Apr 10;24(4):525]. Nat Med. 2016;22(11):1342-1350. doi:10.1038/nm.4191

  15. Seo HM, Chang YS, Joo SH, Kim YW, Park YK, Hong SW, et al. Clinicopathologic cha-racteristics and outcomes of gastric cancers with the MSI-H phenotype. J Surg Oncol. 2009;99(3):143-147. doi:10.1002/jso.21220

  16. Murphy MA, Wentzensen N. Frequency of mismatch repair deficiency in ovarian can-cer: a systematic review. This article is a US Government work and, as such, is in the pu-blic domain of the United States of America. Int J Cancer. 2011;129(8):1914-1922. doi:10.1002/ijc.25835

  17. Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Pro-ject. Clin Cancer Res. 2017;23(15):4441-4449. doi:10.1158/1078-0432.CCR-16-2211

  18. Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, et al. Ge-netic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discov. 2018;8(1):49-58. doi:10.1158/2159-8290.CD-17-0787

  19. Agostini M, Enzo MV, Morandi L. A ten mar-kers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors. Cancer Biomark. 2010;6(1):49-61. doi:10.3233/CBM-2009-0118

  20. Haghighi MM, Javadi GR, Parivar K. Fre-quent MSI mononucleotide markers for diag-nosis of hereditary nonpolyposis colorectal cancer. Asian Pac J Cancer Prev. 2010;11(4):1033-1035

  21. Suraweera N, Duval A, Reperant M. Evalua-tion of tumor microsatellite instability using five quasimonomorphic mononucleotide re-peats and pentaplex PCR. Gastroenterol. 2002;123(6):1804-1811. doi:10.1053/gast.2002.37070

  22. Buhard O, Suraweera N, Lectard A, Duval A, Hamelin R. Quasimonomorphic mononu-cleotide repeats for high-level microsatellite instability analysis. Dis Markers. 2004;20(4-5):251-257. doi:10.1155/2004/159347

  23. Buhard O, Cattaneo F, Wong YF. Multipopu-lation analysis of polymorphisms in five mo-nonucleotide repeats used to determine the microsatellite instability status of human tu-mors. J Clin Oncol. 2006;24(2):241-251. doi:10.1200/JCO.2005.02.7227

  24. Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers [published correction appears in PLoS One. 2010;5(3). doi: 10.1371/annota-tion/572bb6d3-0315-40b1-a6d7-ce818809b5ea]. PLoS One. 2010;5(2):e9393. Published 2010 Feb 24. doi:10.1371/journal.pone.0009393

  25. Luchini C, Bibeau F, Ligtenberg MJL. ESMO recommendations on microsatellite instabi-lity testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232-1243. doi:10.1093/an-nonc/mdz116

  26. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res. 2019;25(13):3753-3758. doi:10.1158/1078-0432.CCR-18-4070

  27. Kok M, Chalabi M, Haanen J. How I treat MSI cancers with advanced disease. ESMO Open. 2019;4(Suppl 2):e000511. Published 2019 May 21. doi:10.1136/esmoopen-2019-000511

  28. Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777-2789. doi:10.1080/21645515.2016.1199310

  29. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc). 2015;51(1):7-20. doi:10.1358/dot.2015.51.1.2250387

  30. Selvajaran G. Pembrolizumab: The Nut Cra-cker. Indian J Med Paediatric Oncology. 2020;41(3):393-396. doi:10.4103/ijmpo.ijmpo_37_20

  31. Gokare P, Lulla AR, El-Deiry WS. MMR-de-ficiency and BRCA2/EGFR/NTRK muta-tions. Aging (Albany NY). 2017;9(8):1849-1850. doi:10.18632/aging.101275

  32. Medina PJ, Adams VR. PD-1 Pathway Inhi-bitors: Immuno-Oncology Agents for Resto-ring Antitumor Immune Responses. Pharma-cotherapy. 2016;36(3):317-334. doi:10.1002/phar.1714

  33. van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, et al. Im-munogenicity of pembrolizumab in patients with advanced tumors. J Immunother Can-cer. 2019;7(1):212. Published 2019 Aug 8. doi:10.1186/s40425-019-0663-4

  34. Chang L, Chang M, Chang HM, Chang F. Mi-crosatellite Instability: A Predictive Biomar-ker for Cancer Immunotherapy. Appl Im-munohistochem Mol Morphol. 2018;26(2):e15-e21. doi:10.1097/PAI.0000000000000575

  35. Sidaway P. MSI-H: a truly agnostic biomar-ker?. Nat Rev Clin Oncol. 2020;17(2):68. doi:10.1038/s41571-019-0310-5

  36. Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, et al. Evaluation of dosing strategy for pembrolizumab for onco-logy indications. J Immunother Cancer. 2017;5:43. Published 2017 May 16. doi:10.1186/s40425-017-0242-5

  37. Goodman AM, Sokol ES, Frampton GM, Li-ppman SM, Kurzrock R. Microsatellite-Sta-ble Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Im-munol Res. 2019;7(10):1570-1573. doi:10.1158/2326-6066.CIR-19-0149

  38. Duffy MJ, Crown J. Biomarkers for Predic-ting Response to Immunotherapy with Im-mune Checkpoint Inhibitors in Cancer Pa-tients. Clin Chem. 2019;65(10):1228-1238. doi:10.1373/clinchem.2019.303644

  39. Rüschoff J, Baretton G, Bläker. MSI testing : What's new? What should be considered?. MSI-Testung : Was ist neu? Was ist zu beachten?. Pathologe. 2021;42(Suppl 1):110-118. doi:10.1007/s00292-021-00948-3

  40. Yamamoto H, Imai K. An updated review of microsatellite instability in the era of next-ge-neration sequencing and precision medicine. Semin Oncol. 2019;46(3):261-270. doi:10.1053/j.seminoncol.2019.08.003




2020     |     www.medigraphic.com